NCT03233399 Modulating Movement Intention Via Cortical Stimulation
| NCT ID | NCT03233399 |
| Status | Recruiting |
| Phase | — |
| Sponsor | NYU Langone Health |
| Condition | Seizures |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2017-07-20 |
| Primary Completion | 2027-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2017-07-20 with a primary completion date of 2027-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this protocol is to learn about movement intention and volition. To improve such knowledge, investigators will conduct sub-studies using multiple non-invasive methodologies. These results could provide preliminary data for subsequent studies evaluating local and global efficacy of plasticity-inducing treatments for PMD symptoms.
Eligibility Criteria
Inclusion Criteria: (Healthy Controls) * Fluent in English (Patients with PMD or PNES): * Diagnosis of PMD/PNES confirmed by a neurologist with expertise in movement disorders. * Per the treating neurologist, subject is unlikely to require treatment and/or dosage changes for 3-6 months following screening Exclusion Criteria: * Any history of a significant neurological disorder, which may interfere with the interpretation of study data, as determined by the PI * Chronic or progressive medical condition * Any history of traumatic brain injury or significant head trauma * Currently meets criteria for substance abuse or dependence * History of any psychotic disorder or other psychiatric condition which may interfere with data interpretation * Pregnancy * Metal or devices in the head, including neurostimulators or metal foreign bodies * Any other implanted metal device, including pacemaker, spinal cord stimulator, VNS. * Any other ferromagnetic substance in the body that may increase study risk (including dental prosthetics, etc.). * Taking tricyclic antidepressant or antiepileptic medications or CNS active drugs under "strong potential hazard" list in Rossi et al., 2009 * Current diagnosis of any inflammatory or autoimmune disorder within last 6 months PMD and PNES Patients * Any history of traumatic brain injury or significant head trauma * Diagnosis of organic seizure disorder, including febrile seizures and tonic-clonic seizures; * Neurological disorder other than PMD and PNES including stroke, fainting spells or syncope of unknown cause(s); * Major or unstable medical illness, especially any current diagnosis of inflammatory or autoimmune disorders within last 6 months * Metal or devices in the head, including neurostimulators or metal foreign bodies * Taking tricyclic antidepressant medications or CNS active drugs under "strong potential hazard" list in Rossi et al., 2009; * Diagnosis of dementia, or Montreal Cognitive Assessment (MoCA) ≤24; * Recurrent visual hallucinations, within the past 6 months; * History of significant uncontrollable movements of the head; * Any clinically significant abnormality on vital signs
Contact & Investigator
Biyu He, MD
PRINCIPAL INVESTIGATOR
NYU Langone Health
Frequently Asked Questions
Who can join the NCT03233399 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Seizures. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03233399 currently recruiting?
Yes, NCT03233399 is actively recruiting participants. Contact the research team at Nalini.Jeet@nyulangone.org for enrollment information.
Where is the NCT03233399 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT03233399 clinical trial?
NCT03233399 is sponsored by NYU Langone Health. The principal investigator is Biyu He, MD at NYU Langone Health. The trial plans to enroll 30 participants.